BD Veritor COVID-19 test now authorized for another OTC use

If your email program has trouble displaying this email, view as a webpage.

FDA - Center for Devices and Radiological Health

Bookmark and Share

FDA Authorizes BD Veritor At-Home COVID-19 Test for Another OTC use

The U.S. Food and Drug Administration (FDA) reissued the emergency use authorization (EUA) for the Becton, Dickinson and Company (BD) Veritor At-Home COVID-19 Test.

The BD Veritor At-Home COVID-19 Test is a diagnostic antigen test that gives results in 15 minutes. The test can be used:

  • Over the counter (OTC), and without a prescription.
  • As a single test for people with COVID-19 symptoms.
  • As a serial test for people without COVID-19 symptoms, meaning the test must be done twice over three days.
  • For people age 14 years and older with a self-collected nasal swab sample or people age 2 years and older when an adult collects the nasal swab sample.

The FDA reissued the EUA to authorize use of the BD Veritor At-Home COVID-19 Test as a single test without a prescription for people with COVID-19 symptoms. The test was already authorized for use as a serial test without a prescription by people with or without COVID-19 symptoms.

Read More

The FDA is committed to increasing the availability of appropriately accurate and reliable at-home COVID-19 diagnostic tests, and to facilitating consumer access to these tests.


If you have questions about OTC COVID-19 tests, see Coronavirus Disease 2019 Testing Basics.